Evaluating BCG Therapy in High- and Low-Grade Non-Muscle-Invasive Bladder Cancer: Insights from a Latvian Hospital (2019–2024)
By:
References
- Bitiņa-Barlote, Ē., Plonis, J., Cauce, V., Vjaters, E., Gardovskis, J., Miklaševičs, E., Nakazawa-Miklaševiča, M. (2021). Bladder cancer trends in Latvia during 1990–2017: Incidence, mortality, and survival rates. Cent. Eur. J. Urol., 74, 14–23. https://doi.org/10.5173/ceju.2021.0266.R2.
- Böhle, A., Jocham, D., Bock, P. R. (2003). Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol., 169, 90–95. https://doi.org/10.1016/S0022-5347(05)64043-8.
- Brausi, M., Oddens, J., Sylvester, R., Bono, A., Van De Beek, C., Van Andel, G., Gontero, P., Turkeri, L., Marreaud, S., Collette, S., Oosterlinck, W. (2014). Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1y with 3 years of maintenance BCG. Eur. Urol., 65, 69–76. https://doi.org/10.1016/j.eururo.2013.07.021.
- Cambier, S., Sylvester, R. J., Collette, L., Gontero, P., Brausi, M. A., Van Andel, G., Kirkels, W. J., Silva, F. C. D., Oosterlinck, W., Prescott, S., et al. (2016). EORTC nomograms and groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guérin. Eur. Urol., 69, 60–69. https://doi.org/10.1016/j.eururo.2015.06.045.
- Catto, J. W. F., Downing, A., Mason, S., Wright, P., Absolom, K., Bottomley, S., Hounsome, L., Hussain, S., Varughese, M., Raw, C., Kelly, P., Glaser, A. W. (2021). Quality of life after bladder cancer: A cross-sectional survey of patient-reported outcomes. Eur. Urol., 79, 621–632. https://doi.org/10.1016/j.eururo.2021.01.032.
- Choi, S. Y., Ha, M. S., Kim, J. H., Chi, B. H., Kim, J. W., Chang, I. H., Kim, T.-H., Myung, S. C. (2022). Low-dose versus standard-dose bacille Calmette-Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig. Clin. Urol., 63, 140–150. https://doi.org/10.4111/icu.20210340.
- Divrik, R. T., ªahin, A. F., Yildirim, Ü., Altok, M., Zorlu, F. (2010). Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial. Eur. Urol., 58, 185–190. https://doi.org/10.1016/j.eururo.2010.03.007.
- Drachneris, J., Rasmusson, A., Morkunas, M., Fabijonavicius, M., Cekauskas, A., Jankevicius, F., Laurinavicius, A. (2023). CD8+ cell density gradient across the tumor epithelium–stromal interface of non-muscle invasive papillary urothelial carcinoma predicts recurrence-free survival after BCG immunotherapy. Cancers, 15, 1205. https://doi.org/10.3390/cancers15041205.
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., Bray, F. (2024). Cancer Today (version 1.1). Global Cancer Observatory. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf.
- Grimm, M.-O., van der Heijden, A. G., Colombel, M., Muilwijk, T., Martínez-Pińeiro, L., Babjuk, M. M., Türkeri, L.N., Palou, J., Patel, A., Bjartell, A. S., Caris, C., Schipper, R. G., Witjes, W. P. J., EAU Research Foundation NIMBUS Study Group (2020). Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS.” Eur. Urol., 78, 690–698. https://doi.org/10.1016/j.eururo.2020.04.066.
- Guallar-Garrido, S., Julián, E. (2020). Bacillus Calmette-Guérin (BCG) Therapy for bladder cancer: An Update. ImmunoTargets Ther., 9, 1–11. https://doi.org/10.2147/ITT.S202006.
- Iida, K., Naiki, T., Kawai, N., Etani, T., Ando, R., Ikegami, Y., Okamura, T., Kubota, H., Okada, A., Kohri, K., Yasui, T. (2016). Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer. BMC Urol., 16, 8. https://doi.org/10.1186/s12894-016-0126-x.
- Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., Kassouf, W. (2016). Bladder cancer. The Lancet, 388, 2796–2810. https://doi.org/10.1016/S0140-6736(16)30512-8.
- Leal, J., Luengo-Fernandez, R., Sullivan, R., Witjes, J. A. (2016). Economic burden of bladder cancer across the European Union. Eur. Urol., 69, 438–447. https://doi.org/10.1016/j.eururo.2015.10.024.
- Liu, Y., Lu, J., Huang, Y., Ma, L. (2019). Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer. J. Oncol., 2019, 1–11. https://doi.org/10.1155/2019/6230409.
- Lobo, N., Hensley, P. J., Bree, K. K., Nogueras-Gonzalez, G. M., Navai, N., Dinney, C. P., Sylvester, R. J., Kamat, A. M. (2022). Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin. Eur. Urol. Oncol., 5, 84–91. https://doi.org/10.1016/j.euo.2021.11.006.
- Lundholm, C., Norlen, B. J., Ekman, P., Jahnson, S., Lagerkvist, M., Lindeborg, T., Olsson, J. O., Tveter, K. W., Westberg, R., Malmstrom, P.-U. (1996). A randomized prospective study comparing long-term intravesical instillations of mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J. Urol., 156, 372–376. https://doi.org/10.1016/S0022-5347(01)65853-1.
- Malmström, P.-U., Sylvester, R. J., Crawford, D. E., Friedrich, M., Krege, S., Rintala, E., Solsona, E., Di Stasi, S. M., Witjes, J. A. (2009). An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur. Urol., 56, 247–256. https://doi.org/10.1016/j.eururo.2009.04.038.
- Martínez-Piñeiro, L., Portillo, J. A., Fernández, J. M., Zabala, J. A., Cadierno, I., Moyano, J. L., Solsona, E., Unda, M., Beardo, P., Rodríguez-Molina, J., et al. (2015). Maintenance therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: Final results of randomised CUETO study 98013. Eur. Urol., 68, 256–262. https://doi.org/10.1016/j.eururo.2015.02.040.
- Morales, A., Eidinger, D., Bruce, A. W. (1976). Intracavitary Bacillus Calmette-guerin in the treatment of superficial bladder tumors. J. Urol., 116, 180–182. https://doi.org/10.1016/S0022-5347(17)58737-6.
- Oddens, J., Brausi, M., Sylvester, R., Bono, A., Van De Beek, C., Van Andel, G., Gontero, P., Hoeltl, W., Turkeri, L., Marreaud, S., Collette, S., Oosterlinck, W. (2013). Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guérin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol., 63, 462–472. https://doi.org/10.1016/j.eururo.2012.10.039.
- OECD, European Observatory on Health Systems and Policies (2023). Latvia: Country Health Profile 2023, State of Health in the EU. OECD. https://doi.org/10.1787/bf2b15d6-en.
- Piszczek, R., Krajewski, W., Subiela, J. D., Del Giudice, F., Nowak, Ù., Chorbiñska, J., Moschini, M., Masson-Lecomte, A., Bebane, S., Cimadamore, A., et al. (2023). Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy. Minerva Urol. Nephrol., 75. https://doi.org/10.23736/S2724-6051.23.05418-6.
- Saunders, C. L., Abel, G. A., Lyratzopoulos, G. (2015). Inequalities in reported cancer patient experience by socio-demographic characteristic and cancer site: Evidence from respondents to the English cancer patient experience survey. Eur. J. Cancer Care (Engl.) 24, 85–98. https://doi.org/10.1111/ecc.12267.
- Scilipoti, P., Moschini, M., Li, R., Lerner, S. P., Black, P. C., Necchi, A., Rouprêt, M., Shariat, S. F., Gupta, S., Morgans, A. K., Psutka, S. P., Kamat, A. M. (2024). The financial burden of localized and metastatic bladder cancer. Eur. Urol., S0302283824027441. https://doi.org/10.1016/j.eururo.2024.12.002.
- Shelley, M.D., Kynaston, H., Court, J., Wilt, T.J., Coles, B., Burgon, K., Mason, M.D., 2001. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int., 88, 209–216. https://doi.org/10.1046/j.1464-410x.2001.02306.x
- Sylvester, R. J., Rodríguez, O., Hernández, V., Turturica, D., Bauerová, L., Bruins, H. M., Bründl, J., Van Der Kwast, T. H., Brisuda, A., Rubio-Briones, J. (2021). European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: An update from the EAU NMIBC guidelines panel. Eur. Urol., 79, 480–488. https://doi.org/10.1016/j.eururo.2020.12.033.
- Sylvester, R J., Van Der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., Kurth, K. (2006). Predicting recurrence and progression in individual patients with dtage Ta T1 bladder bancer Using EORTC Risk Tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol., 49, 466–477. https://doi.org/10.1016/j.eururo.2005.12.031.
- Thiel, T., Ryk, C., Renström-Koskela, L., Steineck, G., Schumacher, M. C., Wiklund, N. P., De Verdier, P. J. (2019). Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer. World J. Urol., 37, 155–163. https://doi.org/10.1007/s00345-018-2375-7.
- Verri, P., Baboudjian, M., Diana, P., Gallioli, A., Territo, A., Gaya, J.M., Huguet, J., Rodriguez-Faba, O., Palou, J., Breda, A., 2023. Reduced- vs full-dose BCG in bladder cancer: A systematic review and meta-analysis. Actas Urol. Esp. Engl., Ed., 47, 4–14. https://doi.org/10.1016/j.acuroe.2022.08.005.
- Wahlen, M. M., Packiam, V. T., Nash, S. H., Carnahan, R. M., Carter, K. D., O’Rorke, M. A., O’Donnell, M., Halpern, M. (2025). The impact of BCG shortage on disease recurrence for patients with non-muscle invasive bladder cancer: A seer patterns of care analysis. Urol. Oncol. Semin. Orig. Investig., 43, 46. https://doi.org/10.1016/j.urolonc.2024.12.117
- Witjes, J. A., Palou, J., Soloway, M., Lamm, D., Brausi, M., Spermon, J. R., Persad, R., Buckley, R., Akaza, H., Colombel, M., Böhle, A. (2008). Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events. Eur. Urol. Suppl., 7, 667–674. https://doi.org/10.1016/j.eursup.2008.08.001.
- Yong, C., Mott, S. L., Steinberg, R. L., Packiam, V. T., O’Donnell, M. A. (2022). A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience. Urol. Oncol. Semin. Orig. Investig., 40, 491.e1-491.e9. https://doi.org/10.1016/j.urolonc.2022.06.007.
Language: English
Page range: 198 - 204
Submitted on: May 26, 2025
Accepted on: Aug 12, 2025
Published on: Sep 27, 2025
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 times per year
Keywords:
Related subjects:
© 2025 Reičela Heinrihsone, Maksimilians Rate, Ērika Bitiņa-Barlote, Juris Plonis, Edvīns Miklaševičs, Miki Nakazawa-Miklaševiča, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution 4.0 License.